Company Overview
| Stock Name | 诺辉健康 - B |
|---|---|
| Stock Code | 06606 |
| Company Full Name | To be extracted |
| Industry | 醫療保健 |
| Principal Activities | 主要在中國從事研發結直腸癌、宮頸癌及其他癌癥的篩查產品。 |
| Listing Date | 2021-02-18 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國浙江省杭州市濱江區江二路400號T1幢13層 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://ir.newhorizonbio.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 26.66 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 47.1% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 1,021,051,340 |
Stock Connect Inclusion
| HK Market Cap | --- |
|---|
| 26Q2 Regular Review | |
| Inclusion Pathway | None |
|---|---|
| Est. Threshold | --- |
| Analysis Result | 无法确定入通路径 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 84.0 |
|---|---|
| First Day Open | HK$ 76.0 |
| First Day Change | 215.08% |
| First Day Volume | 66311800.0 |
| First Day Turnover | 5089270000.0 |
Use of Proceeds
| Use of Proceeds | 1、約40%（或759.4百萬港元），將分配用于為常衛清（作為醫療服務或獨立產品）的商業化及進一步開發提供資金； 2、約5%（或94.9百萬港元），將分配用于通過提高結直腸癌篩查意識及提升市場滲透率為噗噗管的持續銷售及營銷提供資金； 3、約30%（或569.6百萬港元），將分配用于為正在進行及計劃進行的研發提供資金以進一步發展幽幽管、宮證清及其他處于早期階段的管線產品； 4、約15%（或284.8百萬港元），將用于通過潛在收購或外部引進癌癥篩查領域的候選產品持續擴大及多元化本公司的產品組合； 5、約10%（或189.9百萬港元），將用作本公司的營運資金及其他一般企業用途。 |
|---|
Underwriting Syndicate
Overall Coordinators (7)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
UBS Securities Hong Kong Limited CE BIN466
HAITONG INTERNATIONAL SECURITIES COMPANY LIMITED CE AAF806
BOCI ASIA LIMITED CE AET863
CHINA INDUSTRIAL SECURITIES INTERNATIONAL CAPITAL LIMITED CE BAK956
Daiwa Capital Markets Hong Kong Limited CE AAB639
VMS Securities Limited CE AAC621
Joint Bookrunners (7)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
UBS Securities Hong Kong Limited CE BIN466
HAITONG INTERNATIONAL SECURITIES COMPANY LIMITED CE AAF806
BOCI ASIA LIMITED CE AET863
CHINA INDUSTRIAL SECURITIES INTERNATIONAL CAPITAL LIMITED CE BAK956
Daiwa Capital Markets Hong Kong Limited CE AAB639
VMS Securities Limited CE AAC621
Joint Lead Managers (8)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
UBS Securities Hong Kong Limited CE BIN466
HAITONG INTERNATIONAL SECURITIES COMPANY LIMITED CE AAF806
BOCI ASIA LIMITED CE AET863
CHINA INDUSTRIAL SECURITIES INTERNATIONAL CAPITAL LIMITED CE BAK956
Daiwa Capital Markets Hong Kong Limited CE AAB639
VMS Securities Limited CE AAC621
Futu Securities International (Hong Kong) Limited CE AZT137
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Boyu Capital Opportunities Master Fund | 131,793,710 HKD | — | 6.45% | — | 6 months | 2021-08-18 |
| 2 | Columbia Variable Portfolio - Emerging Markets Fund | 38,763,640 HKD | — | 1.90% | — | 6 months | 2021-08-18 |
| 3 | Cormorant Asset Management, LP | 15,516,120 HKD | — | 0.76% | — | 6 months | 2021-08-18 |
| 4 | GIC Private Limited | 77,527,280 HKD | — | 3.80% | — | 6 months | 2021-08-18 |
| 5 | HBC Asia Healthcare Opportunities VII LLC | 23,260,850 HKD | — | 1.14% | — | 6 months | 2021-08-18 |
| 6 | Invesco Advisers, Inc. | 310,095,790 HKD | — | 15.19% | — | 6 months | 2021-08-18 |
| 7 | Janus Henderson Funds | 15,516,120 HKD | — | 0.76% | — | 6 months | 2021-08-18 |
| 8 | Lake Bleu Prime Healthcare Master Fund Limited | 155,054,560 HKD | — | 7.59% | — | 6 months | 2021-08-18 |
| 9 | LAV Amber Limited | 15,516,120 HKD | — | 0.76% | — | 6 months | 2021-08-18 |
| 10 | Octagon Investments Master Fund LP | 15,516,120 HKD | — | 0.76% | — | 6 months | 2021-08-18 |
| 11 | Rock Springs Capital Master Fund LP | 15,516,120 HKD | — | 0.76% | — | 6 months | 2021-08-18 |
| 12 | Sage Partners Master Fund | 15,516,120 HKD | — | 0.76% | — | 6 months | 2021-08-18 |
| 13 | Worldwide Healthcare Trust PLC | 31,018,910 HKD | — | 1.52% | — | 6 months | 2021-08-18 |
| 14 | Yi Fang Da Brocade Inv. Limited | 15,516,120 HKD | — | 0.76% | — | 6 months | 2021-08-18 |
| 15 | 加皇环球资产管理(亚洲)有限公司 | 69,782,550 HKD | — | 3.42% | — | 6 months | 2021-08-18 |
| 16 | 南方基金管理股份有限公司 | 15,516,120 HKD | — | 0.76% | — | 6 months | 2021-08-18 |
Directors & Management
| Chairman | 姚納新 |
|---|---|
| Company Secretary | 梁頴嫻 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 陳一友(10.52%);姚納新及關連人士(8.80%);Qiming Corporate GP V, Ltd(8.35%);朱葉青(6.55%);君聯資本管理股份有限公司(5.35%);SBCVC Fund V, L.P.(5.25%) |
|---|
